
Biogen Inc.
BIIBHealthcare|Drug Manufacturers - General|US
$248.35
+4.42 (+1.81%)
DCF Value
$517.66
Graham Number
$82.35
Cash / Share
$8.82
Next Earnings Report
Feb 5, 2027
EPS est. $2.85 · Revenue est. $2.61B
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.
Upcoming Data Readouts (36)
Dec 2026
Est. completion
P3Early Alzheimer's Disease
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
NCT03887455n=1,906
Jan 2027
Est. completion
Feb 2027
Est. completion
Muscular Atrophy, Spinal
A Study of the Safety of Nusinersen (Spinraza®) and Its Effects on Motor Function in Koreans Living With SMA Treated During Their Usual Medical Care
NCT04317794n=74
Mar 2027
Est. completion
P2Parkinson Disease
Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
NCT06602193n=50
Mar 2027
Est. completion
Postpartum Depression
A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting Zuranolone
NCT07398469n=300
Apr 2027
Est. completion
May 2027
Est. completion
P4Amyotrophic Lateral Sclerosis
A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)
NCT07223723n=12
May 2027
Est. completion
P3Immunoglobulin A Nephropathy (IgAN)
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357n=454
Jun 2027
Est. completion
Sep 2027
Est. completion
Sep 2027
Est. completion
Spinal Muscular Atrophy
Characterizing Perceived Physical Fatigability in Nusinersen-treated SMA
NCT06955897n=45
Sep 2027
Est. completion
P3Spinal Muscular Atrophy
A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)
NCT05067790n=45
Sep 2027
Est. completion
P1Muscular Atrophy, Spinal
A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)
NCT06555419n=78
Oct 2027
Est. completion
P2Multiple Sclerosis
Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)
NCT05418010n=40
Nov 2027
Est. completion
P3Friedreich Ataxia
A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia
NCT06953583n=255
Jan 2028
Est. completion
P2Graves' Disease
A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old
NCT07722546n=60
Apr 2028
Est. completion
NASpinal Muscular Atrophy
Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy
NCT05866419n=90
Jun 2028
Est. completion
Jun 2028
Est. completion
P1Healthy Volunteer
A Study to Learn More About the Safety of a Single Dose of BIIB144 and How it is Processed in the Body of Healthy Adult Participants Ages 18 to 55 Years Old as Compared to a Placebo
NCT07662148n=48
Jun 2028
Est. completion
P3Spinal Muscular Atrophy
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam
NCT07444476n=90
Awaiting Results (4)
Trials past primary completion date but still active — data readout may be imminent.
Oct 2026
A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)
NCT05925049Oct 2026
P2P3
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT05531565Sep 2026
An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
NCT06053749Sep 2026
P3
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT04961567Recent Press Releases
Biogen Provides Update on Private Payer Coverage for ZURZUVAE™ (zuranolone)
Nov 5, 2026 · Business Wire
Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026
Oct 29, 2026 · GlobeNewsWire
Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week
Oct 19, 2026 · GlobeNewsWire
Biogen's Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
Oct 2, 2026 · GlobeNewsWire
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
Sep 17, 2026 · GlobeNewsWire
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer's Disease
Sep 16, 2026 · GlobeNewsWire
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Sep 3, 2026 · GlobeNewsWire
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Sep 3, 2026 · Business Wire
SEC Filings (64)
Last two years from EDGAR. Insider Form 4s are on the Ownership tab.
| Filed | Form | What it is | Links |
|---|---|---|---|
| Oct 28, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Oct 28, 2026 | 8-K | Material event | DocumentIndex |
| Aug 6, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Jul 29, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Jul 29, 2026 | 8-K | Material event | DocumentIndex |
| Jul 1, 2026 | 8-K | Material event | DocumentIndex |
| Jun 10, 2026 | 8-K | Material event | DocumentIndex |
| Jun 10, 2026 | 8-K/A | Material event | DocumentIndex |
| Jun 5, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| May 14, 2026 | SC 13D/A | Activist / 5%+ stake | DocumentIndex |
| May 14, 2026 | 8-K | Material event | DocumentIndex |
| May 14, 2026 | SC TO-T/A | Tender offer | DocumentIndex |
| May 12, 2026 | SC TO-T/A | Tender offer | DocumentIndex |
| May 6, 2026 | SC TO-T/A | Tender offer | DocumentIndex |
| May 6, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Apr 29, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Apr 29, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Apr 29, 2026 | 8-K | Material event | DocumentIndex |
| Apr 28, 2026 | ARS | Annual report to holders | DocumentIndex |
| Apr 28, 2026 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Apr 28, 2026 | DEF 14A | Proxy / shareholder vote | DocumentIndex |
| Apr 14, 2026 | SC TO-T | Tender offer | DocumentIndex |
| Apr 7, 2026 | SC TO-C | Tender offer | DocumentIndex |
| Apr 6, 2026 | SC 13D | Activist / 5%+ stake | DocumentIndex |
| Apr 6, 2026 | 8-K | Material event | DocumentIndex |
| Apr 3, 2026 | SC TO-C | Tender offer | DocumentIndex |
| Mar 31, 2026 | SC TO-C | Tender offer | DocumentIndex |
| Mar 31, 2026 | 8-K | Material event | DocumentIndex |
| Mar 31, 2026 | SC TO-C | Tender offer | DocumentIndex |
| Mar 26, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Mar 11, 2026 | 8-K | Material event | DocumentIndex |
| Feb 11, 2026 | 8-K | Material event | DocumentIndex |
| Feb 6, 2026 | 10-K | Annual report | DocumentIndex |
| Feb 6, 2026 | 8-K | Material event | DocumentIndex |
| Feb 5, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Jan 14, 2026 | 8-K | Material event | DocumentIndex |
| Nov 13, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Nov 10, 2025 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Oct 30, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Oct 30, 2025 | 8-K | Material event | DocumentIndex |